Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives

Academic Article
Publication Date:
2022
Short description:
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives / Margoni, M., Preziosa, P., Filippi, M., Rocca, M.A.. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 269(2022), pp. 1316-1334. [10.1007/s00415-021-10744-x]
abstract:
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disease affecting the central nervous system (CNS), often characterized by the accumulation of irreversible clinical disability over time. During last years, there has been a dramatic evolution in several key concepts of immune pathophysiology of MS and in the treatment of this disease. The demonstration of the strong efficacy and good safety profile of selective B-cell-depleting therapies (such as anti-CD20 monoclonal antibodies) has significantly expanded the therapeutic scenario for both relapsing and progressive MS patients with the identification of a new therapeutic target. The key role of B cells in triggering MS disease has been also pointed out, determining a shift from the traditional view of MS activity as largely being ‘T-cell mediated’ to the notion that MS-related pathological processes involve bi-directional interactions between several immune cell types, including B cells, both in the periphery and in the CNS. This review provides an updated overview of the involvement of B cells in the immune pathophysiology and pathology of MS. We summarize the rationale regarding the use of anti-CD20 therapies and the results of the main randomized controlled trials and observational studies investigating the efficacy and safety profile of rituximab, ocrelizumab, ofatumumab and ublituximab. Suggestions regarding vaccinations and management of MS patients during COVID-19 pandemic with anti-CD20 therapies are also discussed. Finally, therapies under investigation and future perspectives of anti-CD20 therapies are taken into consideration.
Iris type:
1.1 Articolo in rivista
Keywords:
Anti-CD20 therapy; B cells; Disease modifying therapy; Multiple sclerosis; Randomized clinical trials
List of contributors:
Margoni, M.; Preziosa, P.; Filippi, M.; Rocca, M. A.
Authors of the University:
FILIPPI MASSIMO
PREZIOSA PAOLO
ROCCA MARIA ASSUNTA
Handle:
https://iris.unisr.it/handle/20.500.11768/118476
Published in:
JOURNAL OF NEUROLOGY
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0